The current guidelines by the American Academy of Dermatology (AAD) recommend biologics and systemic treatments like methotrexate, cyclosporine, and newer biologics targeting IL-17, IL-23, and TNF-α for moderate to severe psoriasis. The gene discussed is TNF; the disease is psoriasis.